The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Conatumumab (CON) plus FOLFIRI (F) or ganitumab (GAN) plus F for second-line treatment of mutant (MT) KRAS metastatic colorectal cancer (mCRC).
Allen Lee Cohn
No relevant relationships to disclose
Josep Tabernero
Consultant or Advisory Role - Amgen
Juan Maurel
No relevant relationships to disclose
Elzbieta Nowara
No relevant relationships to disclose
Sarita Dubey
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Nigel Baker
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Yong Jiang Hei
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Francesco Galimi
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
SuPin Choo
No relevant relationships to disclose